ArticleSkeletal muscle2026
TRPV1 manipulating polarization of M1/M2 macrophages to promote skeletal muscle regeneration.
Article in Skeletal muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of burosumab on macrophage polarization and TRPV1 expression in children with XLH.Endocrine connections · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSkeletal muscle regeneration is a dynamically complex and multistage process in which balanced polarization of M1/M2 macrophages plays a crucial role. M1/M2 macrophages defend against microbial invasion, regulate tissue repair by engulfing pathogens and cellular debris, and secrete a variety of cytokines. However, the precise molecular mechanisms involved in M1/M2 macrophage polarization during skeletal muscle regeneration remain poorly understood. Transient receptor potential vanilloid 1 (TRPV1) is a cation channel implicated in pain perception and inflammation during tissue repair. This study aimed to investigate the role of TRPV1 in cardiotoxin (CTX)-induced skeletal muscle injury and regeneration, focusing on its impact on macrophage polarization and myogenesis.
methodsUsing a CTX-induced muscle injury model in mice, we examined the effects of TRPV1 on skeletal muscle regeneration, macrophage infiltration, and M1/M2 polarization. Mice were pretreated with capsaicin (CAP, a TRPV1 agonist) and capsazepine (CPZ, a TRPV1 antagonist). In vitro, the impact of TRPV1 on RAW264.7 macrophage polarization and myoblast differentiation was evaluated using co-culture experiments. Histological analysis and expression of TRPV1, MyoD, myogenin, CD86, CD206, Arg1, and IL-6 were assessed by Hematoxylin and Eosin staining, Sirius Red staining, immunofluorescence, western blotting, RT-qPCR and enzyme-linked immunosorbent assay. RAW264.7 macrophages were stimulated with LPS /IFN-γ or IL-4/IL-10 before pretreatment with CAP and CPZ and co-cultured with C2C12 myoblasts. Cell Counting Kit-8, immunofluorescence, western blotting, and Giemsa staining were utilized to evaluate macrophage proliferation, polarization and its effects on C2C12 differentiation.
resultsThe expression of TRPV1 was markedly upregulated following CTX-induced skeletal muscle injury. Activation of TRPV1 by CAP reversed the M1/M2 macrophage imbalance, significantly reduced M1 macrophage infiltration, slightly increased M2 macrophage infiltration, and markedly increased MyoD and myogenin expression, thereby enhancing myogenesis. Additionally, CAP administration dramatically decreased M1-associated marker CD86 while increasing M2-associated marker Arg1 compared with controls or CPZ-treated mice. In vitro, TRPV1 activation inhibited M1 polarization and promoted M2 polarization. Co-culture of C2C12 cells with CAP-pretreated macrophages further implies that enhanced M2 polarization and reduced M1 polarization could be a contributing factor to the facilitation of myoblast differentiation.
conclusionsOur findings indicate that TRPV1 promotes skeletal muscle regeneration at least in part by modulating M1/M2 macrophage polarization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.